Invex Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Invex Therapeutics CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Thomas Duthy	Executive Director	4.1yrs	AU$357.23k	0.38% A$ 19.1k
David McAuliffe	Non-Executive Chairman	5.7yrs	AU$57.24k	4.46% A$ 224.4k
David Wheeler	Non-Executive Director	less than a year	AU$36.17k	Veri yok

4.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: IXC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Invex Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Invex Therapeutics Ltd, Annual General Meeting, Nov 26, 2024

No independent directors

Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director

Less than half of directors are independent

Invex Therapeutics Ltd, Annual General Meeting, Nov 28, 2023

Invex Therapeutics Ltd Announces Board Changes

Recent updates

Invex Therapeutics Ltd, Annual General Meeting, Nov 26, 2024

No independent directors

New major risk - Market cap size

Invex Therapeutics Ltd Announces Appointment of David Wheeler as Non-Executive Director

Less than half of directors are independent

Invex Therapeutics Ltd, Annual General Meeting, Nov 28, 2023

Invex Therapeutics Ltd Announces Board Changes

New major risk - Market cap size

Invex Therapeutics Ltd to Report Q4, 2022 Results on Jan 25, 2023

Invex Therapeutics Ltd Receives Approval for Paediatric Plan from the EMA

Invex Therapeutics Ltd Announces Approval to Commence the IIH EVOLVE Phase III Clinical Trial Received from the New Zealand Medicines and Medical Devices Safety Authority

Invex Therapeutics Ltd Announces First Patient Randomised in Iih Evolve Phase Iii Trial

Less than half of directors are independent

Invex Therapeutics Ltd to Report Q1, 2023 Results on Oct 27, 2022

Less than half of directors are independent

Invex Therapeutics Ltd Announces the Receipt of A Second Human Research Ethics Committee Approval to Commence the IIH EVOLVE Phase III Clinical Trial in Australia

Invex Therapeutics Ltd, Annual General Meeting, Nov 22, 2022

Less than half of directors are independent

Invex Therapeutics Ltd Announces the Receipt of Human Research Ethics Committee Approval and Clinical Trial Notification

Invex Therapeutics Ltd to Report Q4, 2022 Results on Jul 06, 2022

Invex Therapeutics Ltd Receives MHRA Approval to Commence IIH EVOLVE Phase III Clinical Trial in the UK

Less than half of directors are independent

Invex Therapeutics Ltd to Report Q1, 2022 Results on Apr 19, 2022

Invex Therapeutics Ltd Provides Formulation and Manufacturing Update

United States Patent and Trademark Office Grants Trademark for Invex Therapeutics Ltd's Presendin

Invex Therapeutics Ltd Appoints Megan Baldwin as an Independent Non-Executive Director

New 90-day high: AU$0.90

Invex Therapeutics Ltd Appoints Tom Duthy as an Executive Director, Effective 1 October 2020

Full year earnings released - AU$0.06 loss per share

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi